| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5104786 | Value in Health | 2017 | 7 Pages |
Abstract
From a Canadian public health payer's perspective at the present time and drug prices, FOLFIRINOX is the optimal regimen on the basis of the cost-effectiveness criterion. GnP is not cost-effective regardless of the WTP threshold.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Doug MA, MSc, PhD, Yoo-Joung MSc, MD, Kathryn BSc, MSc, Ronak BSc, Keya BSc, Kelly BSc, Henry MSc, Kelvin K.W. MSc, MSc, MD,